Radiotherapy in Pelvic Cancers Doesn't Increase Risk for Second Cancers

Share this content:
Radiotherapy in Pelvic Cancers Doesn't Increase Risk for Second Cancers
Radiotherapy in Pelvic Cancers Doesn't Increase Risk for Second Cancers

For patients with pelvic cancers, the risk for developing a second cancer is not increased with radiotherapy (RT), according to a study published in the Journal of Clinical Oncology.

Lisette M. Wiltink, from the Leiden University Medical Center in the Netherlands, and colleagues examined the long-term probability of developing a second cancer among patients included in the TME, PORTEC-1, and PORTEC-2 trials.

In the TME trial, 1,530 patients with rectal cancer were randomly assigned to preoperative external-beam radiotherapy (EBRT) or no RT; in PORTEC-1, 714 patients with endometrial cancer were randomly assigned to postoperative EBRT versus no RT; and in PORTEC-2, 427 patients with endometrial cancer were randomly assigned to EBRT versus vaginal brachytherapy (VBT).

The researchers observed no significant difference in the probability of second cancers for patients who were treated without RT (10- and 15-year rates, 15.8% and 26.5%, respectively) and those treated with EBRT (10- and 15-year rates, 15.4% and 25.6%, respectively) or VBT (10-year rate, 14.9%). No significant differences were found between treatment arms in the individual trials.

The risk for developing a second cancer was higher for all cancer survivors versus an age- and sex-matched general population, with a standardized incidence ratio of 2.98 for any second cancer.

"Those who underwent EBRT or VBT had no higher probability of developing a second cancer than patients who were treated with surgery alone," the researchers wrote.

One author disclosed financial ties to Amgen.

Reference

  1. Wiltink LM et al. J Clin Oncol. 2014;doi:10.1200/JCO.2014.58.6693.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters